Machine learning-enhanced mapping of suicide risk in Bipolar Disorder: A multi-modal analysis
Journal of Affective DisordersResearch Authors: Saboor Saeed, Huaizhi Wang, Lingzhuo Kong, Yimeng Geng, Jinyu Zhang, Yanmeng Pan, Xu Le, Xuhong Zhang, Ting Ting Liu, Shaohua HuAIIM Authors: Michael Leifer, Layna ParaboschiApproved by President Reda RiffiPublication Date: 9/6/2025Comprehensive Summary
This study aimed to understand demographic, clinical, and biological factors associated with suicide risk in bipolar disorder patients. The study was conducted with 152 patients being split into four groups (no risk, low risk, moderate risk, high risk). These patients were then evaluated with the Mini-International Neuropsychiatric Interview (M.I.N.I), Hamilton Depression Scale-24 (HAMD-24), Young Mania Rating Scale (YMRS), Montgomery-Asberg Depression Rating Scale (MADRS), and Beck Scale for Suicide Ideation (BSSI). Patients’ thyroid function, inflammatory markers, and lymphocyte subsets were also analyzed. In the findings, depressive symptoms were significantly associated with the medium and high-risk groups. Lower free thyroxine levels were often associated with the medium and low risk groups. In the no risk group, higher levels of thyroid hormones and autoantibodies were also seen. The machine learning models in the study achieved 87.1% accuracy in predicting suicide risk. HAMD-24 and MADRS were found to be the strongest predictors of suicide risk by a Random-Forest model with 100 decision trees. In the discussion, the authors discussed the importance of understanding the factors that lead to suicide among bipolar patients.
Outcomes and Implications
This research is important as understanding the factors that may lead to earlier targeted interventions for patients. With new biological markers identified, such as thyroid tests and antibody levels, it could open a path for new research and improve risk detection. For the future, the authors of the study recommend more longitudinal studies conducted in multi-center cohorts so the findings could be generalized.
Connect medicine with AI innovation.
No spam. Only the latest AI breakthroughs, simplified and relevant to your field.